Intervention by clinical pharmacists can improve blood glucose fluctuation in patients with diabetes and acute myocardial infarction: A propensity score‐matched analysis

Abstract

Acute phase hyperglycemia and exaggerated glucose fluctuation may be associated with poor outcomes in diabetic patients after acute myocardial infarction (AMI). This study aimed to determine whether intervention by clinical pharmacists can mitigate blood glucose and glucose fluctuations in these fragile patients. This retrospective study enrolled patients with diabetes and AMI, from 1 January 2019 to 30 June 2020 in our institution. Blood glucose and glucose fluctuations were calculated before and after the pharmacist's intervention and between patients who underwent intervention and those who did not. Propensity score matching (PSM) was used to reduce the impact of patient characteristics on the results. A total of 170 patients were included in our primary analysis, including 29 patients who received the pharmacist intervention and 141 patients who did not. After the pharmacist's intervention, blood glucose (fasting blood glucose‐FBG, from 11.9 to 9.8; postprandial blood glucose‐PBG, from 15.3 to 13.2; mean blood glucose‐BG, 14.5 to 12.3 mmol/L; p < .001), and glucose fluctuations (standard deviation of blood glucose‐SDBG, from 3.8 to 3.0, mmol/L, p = .005) were significantly improved. Before PSM, no clear effects were found in intervention versus nonintervention patients, in terms of blood glucose and glucose fluctuation indicators, except for FBG (9.3 vs. 8.0. mmol/L, p = .005). Further analysis indicated a high incidence of FBG <7.8 mmol/L in nonintervention versus intervention patients (51.5% vs. 27.6%, p = .003). After PSM, a significant reduction in blood glucose fluctuation (SDBG, 3.0 vs. 4.1, p = .031; PBGE, 2.1 vs. 4.1, p = .017; LAGE, 4.7 vs. 7.2, mmol/L, p = .004), and PBG (11.1 vs. 13.0, mmol/L, p = .048) was observed in the intervention group than in the nonintervention group. The clinical pharmacist intervention contributed to improved outcomes, specifically, in reducing blood glucose fluctuations and potential hypoglycemia risk.

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes

“…A series of methods can effectively reduce glucose fluctuation in diabetic patients. Shi, F. H ( 21 ) found that the clinical pharmacist intervention contributed to improved outcomes, specifically, in reducing blood glucose fluctuations and potential hypoglycemia risk. However, some drugs have advantages in controlling glucose homeostasis.…”

A Glycemic Diet Improves the Understanding of Glycemic Control in Diabetes Patients During Their Follow-Up

“…They will discuss with the patient to evaluate their practice on therapies, glucose monitoring, diet, and exercise. The intervention for each patient will be noted and intimated to the diabetes care team [ 6–8 ].…”

Pharmacist-Managed Diabetes Programs: Improving Treatment Adherence and Patient Outcomes

“…Through consultation and protocol development, improved hyperglycemia management by pharmacists is possible. 40,41 Solid organ transplantation (SOT) has seen many successes with the addition of the pharmacist into the care team. Posttransplant, up to 90% of patients can experience transient hyperglycemia that often requires short-term treatment with antihyperglycemic agents, while others may go on to develop post-transplant diabetes.…”

“…9,15,18 Studies that looked at the use of telehealth-based visits saw similar improvements in A1c. 49,50 Other diabetes-specific outcomes reported on include time to treatment intensification, 25 time needed to reach A1c goal, 22 number of daily insulin injections, daily units of insulin injected, 11 diabetes-related interventions made per patient per year, 8 reduction in fluctuation of blood glucose, hypoglycemia reduction, 40 appropriate deprescribing, 51 and patient and clinician reported barriers to achieve glycemic control. 18…”